568 related articles for article (PubMed ID: 16251898)
1. Analysing DNA patents in relation with diagnostic genetic testing.
Verbeure B; Matthijs G; Van Overwalle G
Eur J Hum Genet; 2006 Jan; 14(1):26-33. PubMed ID: 16251898
[TBL] [Abstract][Full Text] [Related]
2. Your money or your life.
Westphal SP
New Sci; 2002 Jul; 175(2351):28-33. PubMed ID: 12625339
[No Abstract] [Full Text] [Related]
3. Europe to pay royalties for cancer gene.
Abbott A
Nature; 2008 Dec; 456(7222):556. PubMed ID: 19052591
[No Abstract] [Full Text] [Related]
4. Genetic patent singles out Jewish women.
Abbott A
Nature; 2005 Jul; 436(7047):12. PubMed ID: 16001030
[No Abstract] [Full Text] [Related]
5. Critics question BRCA2 patent decision in Europe.
Steimle S
J Natl Cancer Inst; 2005 Sep; 97(18):1326. PubMed ID: 16174851
[No Abstract] [Full Text] [Related]
6. [Opposition to Myriad Genetics patents and their total or partial revocation in Europe: early conclusions].
Cassier M; Stoppa-Lyonnet D
Med Sci (Paris); 2005; 21(6-7):658-62. PubMed ID: 15985212
[TBL] [Abstract][Full Text] [Related]
7. Intellectual property. In a flurry of metaphors, justices debate a limit on gene patents.
Marshall E
Science; 2013 Apr; 340(6131):421. PubMed ID: 23620028
[No Abstract] [Full Text] [Related]
8. [Revocation of the BRCA1 patents by the European Office of Patents: a victory over a rights abuse].
Stoppa-Lyonnet D; Lenoir G
Bull Cancer; 2005 Apr; 92(4):410-1. PubMed ID: 15888396
[No Abstract] [Full Text] [Related]
9. Malta provides loophole for breast-cancer screen.
Check E
Nature; 2002 Oct; 419(6909):767. PubMed ID: 12397316
[No Abstract] [Full Text] [Related]
10. High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia.
Torres D; Rashid MU; Gil F; Umana A; Ramelli G; Robledo JF; Tawil M; Torregrosa L; Briceno I; Hamann U
Breast Cancer Res Treat; 2007 Jun; 103(2):225-32. PubMed ID: 17080309
[TBL] [Abstract][Full Text] [Related]
11. Cancer risk assessment and the genetic counseling process: using hereditary breast and ovarian cancer as an example.
Prucka SK; McIlvried DE; Korf BR
Med Princ Pract; 2008; 17(3):173-89. PubMed ID: 18408385
[TBL] [Abstract][Full Text] [Related]
12. Hereditary breast-ovarian cancer: clinical findings and medical management.
Marshall M; Solomon S
Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820
[TBL] [Abstract][Full Text] [Related]
13. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility.
Wolff TA; Wilson JE
Am Fam Physician; 2006 Nov; 74(10):1759-60. PubMed ID: 17137007
[No Abstract] [Full Text] [Related]
14. [Gene chips and predictive medicine: Where is gene diagnostics standing today?].
Kaulen H
Dtsch Med Wochenschr; 2003 Jan; 128(5):181-2. PubMed ID: 12596778
[No Abstract] [Full Text] [Related]
15. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.
Gallardo M; Silva A; Rubio L; Alvarez C; Torrealba C; Salinas M; Tapia T; Faundez P; Palma L; Riccio ME; Paredes H; Rodriguez M; Cruz A; Rousseau C; King MC; Camus M; Alvarez M; Carvallo P
Breast Cancer Res Treat; 2006 Jan; 95(1):81-7. PubMed ID: 16261400
[TBL] [Abstract][Full Text] [Related]
16. Molecular and in silico analysis of BRCA1 and BRCA2 variants.
Tommasi S; Pilato B; Pinto R; Monaco A; Bruno M; Campana M; Digennaro M; Schittulli F; Lacalamita R; Paradiso A
Mutat Res; 2008 Sep; 644(1-2):64-70. PubMed ID: 18694767
[TBL] [Abstract][Full Text] [Related]
17. European patents. BRCA2 claim faces new challenge.
Marshall E
Science; 2005 Jun; 308(5730):1851. PubMed ID: 15976277
[No Abstract] [Full Text] [Related]
18. DNA diagnosis and the emergence of cancer genetic services in European health care.
Stemerding D; Koch L; Bourret P
Eur J Hum Genet; 1997; 5 Suppl 2():25-30. PubMed ID: 9450191
[No Abstract] [Full Text] [Related]
19. Receiving inconclusive genetic test results: an interpretive description of the BRCA1/2 experience.
Maheu C; Thorne S
Res Nurs Health; 2008 Dec; 31(6):553-62. PubMed ID: 18449940
[TBL] [Abstract][Full Text] [Related]
20. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
